Fresenius Debuts Subcutaneous Tocilizumab Biosimilar In US

Launches SC Version Of Tyenne Alongside Existing Intravenous Presentation

 
• By Dave Wallace

Fresenius Kabi has become the first firm to market a subcutaneous tocilizumab biosimilar in the US, introducing an SC version of its Tyenne rival to Actemra just a couple of months after the intravenous launch.

Fresenius Kabi logo on building
Fresenius Kabi has launched a new presentation of Tyenne • Source: Shutterstock

More from Biosimilars

More from Products